Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 6/20 | 0.48 |
| ▸ | CHRNA6 | Q15825 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608991 | 1.00 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24884312 | 1.00 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL22169156 | 1.00 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL7149386 | 0.98 | NR1H2 (0.49) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL18081207 | 0.93 | NR1H2 (0.47) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL1979623 | 0.91 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25409415 | 0.91 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL994561 | 0.91 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL18038711 | 0.91 | NR1H2 (0.43) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL4321473 | 0.90 | HPGD (0.48) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865969-A | Preparation method of 3, 8-diazabicyclo [3.2.1] octane-3-tert-butyl formate | 杭州国瑞生物科技有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624052-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| CN-122029167-A | Condensed heteroaryl compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| US-7348343-B2 | Amides useful for treating pain | ABBOTT LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348343-B2 | Amides useful for treating pain | ABBOTT LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348343-B2 | Amides useful for treating pain | ABBOTT LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070010557-A1 | Novel amides useful for treating pain | ABBVIE INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010557-A1 | Novel amides useful for treating pain | ABBVIE INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010557-A1 | Novel amides useful for treating pain | ABBVIE INC. | 2007-01-11 | — | — | US | disclosed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009841-A1 | Novel amides useful for treating pain | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009841-A1 | Novel amides useful for treating pain | OPRL1, OPRK1, FAAH2 | NR1H2 263/4885CHRNB2 231/4885CHRNA3 148/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | NR1H2 220/4885CHRNB2 1691/4885CHRNA3 1029/4885 |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | NR1H2 585/4885CHRNB2 685/4885CHRNA3 360/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | NR1H2 544/4885CHRNB2 352/4885CHRNA3 221/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | NR1H2 430/4885CHRNB2 20/4885CHRNA3 11/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | NR1H2 2537/4885CHRNB2 652/4885CHRNA3 987/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | NR1H2 19/4885CHRNB2 1225/4885CHRNA3 1062/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | NR1H2 2556/4885CHRNB2 4706/4885CHRNA3 4790/4885 |
| US-12624052-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | NR1H2 299/4885CHRNB2 1476/4885CHRNA3 2156/4885 |
| US-20070010557-A1 | Novel amides useful for treating pain | OPRL1, PDE6B, PDE6G | NR1H2 530/4885CHRNB2 2225/4885CHRNA3 1470/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | NR1H2 134/4885CHRNB2 6/4885CHRNA3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.